Spirometer Market Size Worth USD 3.72 Billion by 2035 | SNS Insider

The U.S. spirometer market is forecast to rise from $317.39M in 2025 to $1.90B by 2035, while Europe is projected to grow from $376.92M to $984.78M over the same period. Growth drivers cited include higher respiratory disease screening, increased adoption of portable spirometry, and AI-powered pulmonary diagnostics. Overall, the outlook is supportive but likely limited near-term impact since this is a market projection rather than company-specific results.

Analysis

The investable angle is not the device itself; it is the shift in where and how pulmonary data gets generated. If spirometry moves from specialty labs into primary care, pharmacies, and home monitoring, the margin pool migrates toward whoever owns the workflow, cloud interpretation, and patient follow-up layer, while standalone hardware becomes more commoditized and price-competitive. That favors larger medtech platforms with service revenue and software attach, and it pressures centralized testing volumes that rely on higher-ASP lab work.

The near-term market impact should be limited because reimbursement, clinical adoption, and integration into EMR workflows tend to lag forecast curves by quarters to years. The first real catalyst is not demand speculation but evidence that payers will reimburse broader screening or that major health systems are standardizing portable workflows; absent that, the growth story remains a TAM slide rather than earnings delta. Tail risk is that AI-assisted interpretation introduces liability and false-positive concerns, slowing adoption even if units grow.

Consensus may be overreading the headline CAGR: this is a small market relative to public medtech portfolios, so the biggest beneficiaries may be second-order—device incumbents with bundled software, not pure-play spirometer vendors. The contrarian view is that the move is likely under-monetized in earnings but over-discussed in narrative terms; until reimbursement proof shows up, the right stance is selective exposure, not a broad thematic chase. A reversal would come from flat utilization or payer pushback, which would compress the multiple premium attached to "AI diagnostics" adjacencies.

Key Decisions for Investors

• No standalone trade on the spirometer theme today; treat as a watch item until there is evidence of reimbursement or workflow adoption translating into revenue.
• 6-12 month relative-value idea: long IHI / short XBI. If diagnostic digitization gains traction, profitable medtech/platform names should monetize it faster than unprofitable biotech, with lower fundamental risk.
• If channel checks confirm reimbursement expansion, initiate a small 12-18 month call-spread position in GEHC as a proxy for AI-enabled diagnostic workflow attach; otherwise avoid paying theta for a story trade.
• Set an alert on hospital outpatient PFT volumes and CMS/payer commentary; a disappointment there would falsify the bullish adoption thesis and argue for staying defensive on medtech multiples.
• Avoid chasing small-cap diagnostic software names on this headline alone; liquidity and execution risk are likely to outweigh the incremental addressable revenue in the next 2-3 quarters.